( SAN DIEGO--(BUSINESS WIRE)--Jun 7 2007...)Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology,Health

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that the company's partner, Vical Incorporated, presented positive interim safety and tolerability data on 18 subjects from an ongoing Phase I clinical trial using Inovio's electroporation technology for intratumoral delivery into melanoma tumors of plasmid DNA (pDNA) encoding interleukin-2 (IL-2). The treatment demonstrated objective tumor responses in treated and untreated lesions. The data were presented at the annual meeting of the American Society of Clinical Oncology (Chicago, June 1-5) by Jon M. Richards, M.D., Ph.D., Lutheran General Hospital Division of Hematology/Oncology. Inovio's DNA delivery systems are designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

The systemic delivery of high-dose recombinant IL-2 to treat melanoma is limited by significant toxicity. An alternative method for extended dosing of IL-2 that may reduce toxicity is by intratumoral injection (followed by electroporation to facilitate cellular uptake) of a plasmid DNA designed to produce IL-2 in the body. The primary objective of this ongoing Phase I pDNA IL-2/electroporation study is to evaluate the safety and tolerability of the latter approach in stage three and four metastatic melanoma patients. In the first stage of the trial, four treatment groups received escalating doses of 0.5, 1.5, 5 (mg per tumor), and 15 mg (5 mg in each of 3 tumors). In the ongoing second stage, patients are treated with the 15 mg dose.

The interim study results show that no serious adverse events related to the study drug or administration procedure have been reported and the treatment was well tolerated. The majority of related adverse events
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal